Effective low Dosage, broad Spectrum Antibiotic 

Chemical charasteristics : 
(2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-didoxy 3-C-methyl-3-O-methyl- ? ?-L-ribo-hexopyranosyl) oxy]-2-ethyl- 3,4, 10-trihydroxy-3, 5,6,8,10,12, 14-heptamethyl-11- [ [3,4,6- Trideoxy-3- (dimethylamino)- ? ?-D-xylo-hexopyranosyl] oxy]-1-oxa-6- azacyclopentadecan-15-one. Formula and Molecular Weight: C38H72N2O12 (anhydrous)...748.993 C38H72N2O12 .2H2O......785.02 

Mode of Action : 

Azithromycin is a macrolid antibiotic. It acts by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus,interfering with microbial protein synthesis. Nucleic acid synthesis is not affected. 

Pharmacokinetics :

Azithromycin is rapidly absorbed and widely distributed throughout the body. Rapid distribution of Azithromycin into tissues and high concentration within cells result in significantly higher Azithromycin concentration in tissues than in plasma or serum. One gr. single dose packet is bio equivalent to four 250 mg capsules.Plasma concentration of Azithromycin following single 500mg oral and IV doses declined in a polyphasic pattern results an average terminal half-life of 68 Hours. When Azithromycin capsules are administered with food, the rate of absorption (CMAX) of Azithromycin is reduced by 52% and the extent of absorption (AUC, area under the curve) reduced by 43%. The AUC of Azithromycin in a 250mg capsule is not affected by co administration of an anti Acid containing Aluminum and Magnesium Hydroxide with Azithromycin; however, the CMAX was reduced by 24% administrated of cimitidine (800mg) two hours prior to Azithromycin had no effect on Azithromycin absorption. 

Indications :
Azithromycyn is indicated for treatment of mild to moderate infections caused by susceptible strains of then designated microorganisms in specific conditions of upper and lowerrespiratory tract infections, including pharyngitis, tonsillitis, and pneumonia, cervix or urinary tract infection and moderate skin infections. 

Bulk production of Azithromycin in Shafa plant :
Azithromycin is a derivative of Erythromycin which its share of world market has been growing since it was introduced to the physicians.
Low number of Dosage, short cource of treatment, high oral biological utilization and good osmosis, make Azithromycin a new drug in the world. It has been produced by Shafa since 2005 in conformity with the latest international standards, such as : USP / BP / EP / and IP. 

Procedure of Azithromycin production in Shafa in brief :
1) Preparation of Erythromycin oxime from Erythromycin Base.
2) Preparation of Erythromycin imino ether from Erythromycin oxime.
3) Preparation of Aza-erythromycin from erythromycin imino ether.
4) Preparation of Azithromycin from Aza-erythromycin.
5) Recrystallization of Azithromycin.
6) High purity Azithromycin.

General Information :

Azithromycin is presented to pharmaceutical companies as an API in order to produce various forms of medicines (tablet, syrup, capsule). This company has recieved three national patents and as about to get one international patent for Azithromycin . 

The advantages of Shafa's Azithromycin in comparison with the competitors are : 
- Unique purity quality
- Halal Certification awarded from Islamic Chamber Research & Information Center (ICRIC) 
- Production under GMP certificate (Good Manufacturing Practice) from Ministry of Health
- Production under ISO 9001 certificate 

Opportunities for Cooperation :

Shafa Co. welcomes cooperation with other companies in the field of joint production and marketing. 


طراحی و سئو سایت توسط نونگار